Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 13, 2009

Beckman Coulter Creates Genomics Services Company

  • Beckman Coulter has established Beckman Coulter Genomics, which combines Agencourt Bioscience and the newly acquired Cogenics. It offers researchers a single genomic services resource with expanded global capabilities.

    Beckman Coulter Genomics' team has expertise and experience on a wide range of genomic technology platforms and is dedicated to delivering the highest-quality results, the firm points out. Services currently available through Beckman Coulter Genomics include sequencing, sample preparation, genotyping, gene expression, biological efficiency, and safety testing, with support for all levels of regulatory compliance including CLIA.

    In addition, Beckman Coulter Genomics offers all three commercially available next-generation sequencing platforms: Roche 454 Genome Sequencer FLX with Titanium, Applied Biosystems SOLiD, and Illumina Genome Analyzer.

    “We understand that each customer, each sample, and each study is unique and extremely important,” says Susan Evans, Ph.D., general manager of Beckman Coulter Genomics. “That is why we strive to create a partnership with each customer through a consistent and personalized approach. Our experienced team has the energy and resolve needed to deliver high-quality results scientists can trust, on time and on budget.”

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »